Satisfaction with treatment among patients with psoriasis: a web-based survey study

Cranenburgh, O.D. van; Korte, J. de; Sprangers, Mirjam A. G.; Rie, Menno A. de; Smets, Ellen M. A.

doi:10.1111/bjd.12372

Cited by 80 publications

(102 citation statements)

References 35 publications

(69 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…High impact of the treatment modality on satisfaction scores and greatest satisfaction with biologicals were confirmed in regression models controlling for several confounding factors. These results are well in line with several other studies (2,11,12,14,(20)(21)(22) and may be attributed to the high efficacy, favourable risk-benefit profile and convenient application mode of biologicals.…”

Section: Discussionsupporting

confidence: 91%

See 1 more Smart Citation

Treatment Satisfaction of Patients with Psoriasis

Schaarschmidt¹,

Kromer²,

Herr³

et al. 2015

Acta Derm Venerol

View full text Add to dashboard Cite

Treatment satisfaction of patients with psoriasis largely depends on the treatment modality, but evidence on preferences for specific medications is scarce. Here we assessed treatment satisfaction of 200 participants with moderate-to-severe psoriasis from a German University hospital with a 5-point scale and the Treatment Satisfaction Questionnaire for Medication (TSQM) and determined sociodemographic and disease-related influence factors. Participants obtaining biologicals and traditional systemic medications were significantly more satisfied than those receiving phototherapy or topical agents (TSQM = 323.3, 288.0, 260.6 or 266.8; p < 0.001). The highest TSQM score was calculated for ustekinumab (350.1), followed by acitretin (338.1), adalimumab (323.0), fumaric acid esters (304.7), infliximab (300.2), etanercept (298.8), and methotrexate (272.3; p < 0.001). High disease-related quality of life impairment (β = -0.437, p < 0.001) and psoriatic arthritis (β = -0.185, p = 0.005) were associated with decreased satisfaction. Optimising satisfaction is essential to improve adherence and outcome. We show high preferences for biologicals, particularly ustekinumab, but also good satisfaction with certain traditional medications.

show abstract

Section: Discussionsupporting

confidence: 91%

“…However, several recent studies showed higher satisfaction rates for biologicals than for other treatment modalities (10)(11)(12)(13)(14). Patients' satisfaction with and preferences for specific systemic antipsoriatic medications have only been compared in a few studies, sometimes with conflicting findings (8,11,15,16).…”

mentioning

confidence: 99%

Treatment Satisfaction of Patients with Psoriasis

Schaarschmidt¹,

Kromer²,

Herr³

et al. 2015

Acta Derm Venerol

View full text Add to dashboard Cite

show abstract

“…Topical therapies for psoriasis are generally associated with poor treatment satisfaction, poor adherence due to low efficacy, treatment inconvenience, unsatisfactory cosmetic appearance of the medications, and undesired side effects with long term use. 18–20,31–33 Thus our data suggest that a decrease in prescription topical medication use may contribute to improvements in QoL associated with skin clearance.…”

Section: Discussionmentioning

confidence: 66%

“…We hypothesized that patients with clear skin would be more likely to report lower DLQI scores corresponding to lesser impact of their skin disease on QoL compared to patients with almost clear skin. Secondarily, especially since topical medication use has been associated with poor treatment satisfaction, 18–20 we also aimed to assess the differences in prescription topical medication use in patients with clear versus almost clear skin.…”

Section: Introductionmentioning

confidence: 99%

Patient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting

Takeshita¹,

Duffin²,

Shin³

et al. 2014

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Background There is little evidence to guide the establishment of treatment goals for moderate-to-severe psoriasis in the clinical setting. Objective To compare Dermatology Life Quality Index scores and prescription topical medication use between patients with clear versus almost clear skin. Methods Multicenter cross-sectional study of 97 patients with clear skin and 441 patients with almost clear skin receiving current systemic therapy or phototherapy for a primary indication of plaque psoriasis evaluated at one of ten US outpatient dermatology sites participating in the Dermatology Clinical Effectiveness Research Network. Results In adjusted analyses, patients with clear versus almost clear skin were more likely to report no impact of psoriasis on quality of life (relative risk 1.60; 95% confidence interval, 1.37–1.86). Patients with clear versus almost clear skin were also more likely to report no prescription topical medication use in the preceding week (relative risk 2.08; 95% confidence interval, 1.73–2.49). Limitations Cross-sectional design prohibits longitudinal assessment of outcomes. Conclusions and Relevance Clinically important differences in quality of life and prescription topical medication use exist between patients with clear versus almost clear skin. Collectively, our results indicate that achievement of clear skin may be an important clinical distinction among patients with moderate-to-severe psoriasis.

show abstract

“…The most important element contributing to this satisfaction is effectiveness of the administered therapy, which should be accompanied by good contact with medical personnel, active participation of the patient in taking therapeutic decisions, his/her sufficient knowledge of the disease, skin care methods and potential adverse effects of administered medication [2][3][4][5][6][7][8][9][10][11][12][13]. Studies of adult psoriasis patients confirm that there is a significant correlation between treatment satisfaction and satisfaction with life in general [14,15], self-perception and perception of the world [15], and the role of emotions in the way of the patient's acting and thinking [16]. Fulfillment of patients' preferences regarding the management of psoriasis improves their satisfaction with the therapy [14,16].…”

mentioning

confidence: 99%

Satisfaction with treatment of atopic dermatitis in children

Maciejewska-Franczak¹,

Majak²,

Kaczmarek³

et al. 2016

View full text Add to dashboard Cite

Introduction. Atopic dermatitis is a frequent chronic skin disease in children. The major clinical manifestations include itching and dryness of the skin. The pathomechanism of skin changes results from an interaction of genetic and environmental factors as well as impairments of skin barrier function and immune response. Despite chronic treatment the disease is characterized by exacerbation and remission periods and lowers the quality of life of patients and their families. Objective. To evaluate treatment satisfaction in children with atopic dermatitis, identify components of medical care which contribute to treatment satisfaction, and evaluate the relationship between satisfaction and adherence to a doctor's recommendations. Material and methods. One hundred and nineteen children (6 months to 12 years old, mean age 4.9 years) with atopic dermatitis were enrolled in the study. The doctor performed physical examinations and history taking and filled in questionnaires evaluating the course and exacerbation of the disease, the type of administered therapy and diagnostics. The patients' parents completed two questionnaires: a questionnaire assessing satisfaction with the therapy (the type of recommended therapy, adherence to recommendations, contact with the doctor, obtained information, degree of psychological support, role of parents in taking decisions regarding the therapy) and a quality of life questionnaire. Results. The authors observed that 56% of parents were dissatisfied with the administered treatment, and 40% failed to adhere to at least one therapeutic recommendation. Parents of children with mild atopic dermatitis significantly more often stop using emollients. It was also observed that lack of treatment satisfaction in children with severe atopic dermatitis whose parents are insufficiently educated contributes to decreased adherence. The authors identified independent factors of lack of treatment satisfaction: failure to obtain enough psychological support (OR = 20.00), failure to obtain reliable information on the disease (OR = 5.91), failure to actively get engaged in the treatment procedure (OR = 5.31), dissatisfaction with the contact with the doctor (OR = 4.9), dissatisfaction with the diagnostics (OR = 4.93) and severe course of the disease (OR = 2.82). Conclusions. Elimination of risk factors of dissatisfaction with the treatment might potentially improve the adherence to chronic treatment in atopic dermatitis. atopic dermatitis, satisfaction with treatment. Wprowadzenie. Atopowe zapalenie skóry (AZS) jest częstą przewlekłą chorobą skóry u dzieci. Głównymi objawami klinicznymi są suchość skóry i świąd. Patomechanizm zmian skórnych jest wynikiem interakcji między czynnikami genetycznymi, środowiskowymi, zaburzeniami funkcjonowania bariery skórnej a odpowiedzią immunologiczną. Pomimo stosowania przewlekłego leczenia choroba przebiega z okresami zaostrzeń i remisji, obniża jakość życia pacjentów i ich rodzin. Cel pracy. Próba zdefiniowania składowych opieki medycznej, które mają wpływ n...

show abstract

Satisfaction with treatment among patients with psoriasis: a web-based survey study

Abstract: From the perspective of patients, biologic treatment is promising. To improve further the quality of psoriasis care, the effectiveness and convenience of topical therapies, the safety of systemic therapies, and doctors' communication skills need to be addressed.

Cited by 80 publications

References 35 publications

Treatment Satisfaction of Patients with Psoriasis

Treatment Satisfaction of Patients with Psoriasis

Patient-reported outcomes for psoriasis patients with clear versus almost clear skin in the clinical setting

Satisfaction with treatment of atopic dermatitis in children

Contact Info

Product

Resources

About